Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3

Methodology|Interests|Funding|Corrections

Cycle record

Assessment cycle 2024 Q3 — page 2

Documents ratified in the 2024 Q3 assessment cycle, which ran from 1 July 2024 to 30 September 2024 and was ratified on 18 September 2024.

Documents ratified

43 documents · page 2 of 2

Supplier dossier: Sangon Biotech (Shanghai) Co., Ltd.

CEI-SD-05Supplier dossier2024-q3

Peptides, SARMs, injectable oils and raw materials. Established life-science reagent operation.

15 Jan 2025
Supplier dossier: Wuhan Wansheng Biotechnology Co., Ltd.

CEI-SD-15Supplier dossier2024-q3

Peptides, SARMs, injectables and raw materials. 388 published third-party test reports at the date of assessment.

12 Nov 2024
Supplier dossier: Zhuhai Kerui Biotechnology Co., Ltd.

CEI-SD-16Supplier dossier2024-q3

Peptides, SARMs, injectable oils and raw materials.

11 Jul 2025

page 2 of 2

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.